文献速递浆细胞疾病

表达碘化钠同向转运体的埃德蒙顿株麻疹病毒全身给药治疗复发或难治性多发性骨髓瘤的I期试验

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
PubMed 文献 · Leukemia · 2017-04-25

MV-NIS是一种表达人碘化钠同向转运体的埃德蒙顿株溶瘤麻疹病毒,可通过放射性碘无创成像监测。32例复发难治性骨髓瘤患者接受静脉MV-NIS治疗,队列1未达最大耐受剂量,最高剂量TCID50 1011用于单药II期试验;1例完全缓解,8例123I扫描阳性。

要点

  • 队列1未达最大耐受剂量,TCID50 1011为单药II期试验所用剂量。
  • 两队列所有剂量组3-4级不良事件包括中性粒细胞减少9例、白细胞减少5例、血小板减少2例。
  • 1例完全缓解,其他患者可见血清游离轻链短暂下降。

核心结论

  • MV-NIS能在被免疫系统清除前复制,溶瘤病毒为靶向感染和破坏播散性骨髓瘤提供了有前景的新模式。

研究设计与样本

  • I期试验,纳入已尝试所有其他治疗选择的复发难治性骨髓瘤患者,共32例接受治疗;队列1接受静脉MV-NIS,队列2在MV-NIS前2天接受环磷酰胺。

主要发现

  • 队列1最初入组四个剂量水平未达最大耐受剂量,后因病毒生产技术进步又入组两个更高剂量水平;队列1未达最大耐受剂量,TCID50 1011为单药MV-NIS II期试验所用剂量。
  • 两队列所有剂量组3-4级不良事件:中性粒细胞减少9例;白细胞计数降低5例;血小板减少2例;CD4淋巴细胞减少、贫血和淋巴细胞减少各1例。
  • MV-N RNA序列可从漱口液、血液和尿液中扩增;123I扫描在8例患者中阳性;1例患者达到完全缓解;其他患者可见血清游离轻链短暂下降。

关键数值与推荐

  • 队列1未达最大耐受剂量,TCID50 1011为单药MV-NIS II期试验所用剂量。
  • 两队列所有剂量组3-4级不良事件例数:中性粒细胞减少9例、白细胞计数降低5例、血小板减少2例、CD4淋巴细胞减少1例、贫血1例、淋巴细胞减少1例。
  • 123I扫描阳性8例;完全缓解1例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MV-NIS is an Edmonston lineage oncolytic measles virus expressing the human sodium iodide symporter-a means for monitoring by non-invasive imaging of radioiodine. Patients with relapsed, refractory myeloma who had explored all other treatment options were eligible for this Phase I trial. Cohort 1 was treated with intravenous MV-NIS, and Cohort 2 received cyclophosphamide 2 days prior to MV-NIS. Thirty-two patients were treated. Cohort 1 initially enrolled to four dose levels without reaching maximum tolerated dose (MTD) and subsequently to two higher dose levels when improved virus manufacture technology made it possible. MTD was not reached in Cohort 1, and TCID50 1011 is the dose being used in a Phase II trial of single agent MV-NIS. Grade 3-4 adverse events in both cohorts at all dose levels were: neutropenia (n=9); leukocyte count decreased (n=5); thrombocytopenia (n=2); and CD4 lymphocytes decreased, anemia and lymphopenia (each n=1). MV-N RNA sequences were amplified from gargle specimens, blood and urine. 123I scans were positive in eight patients. One patient achieved a complete response; transient drops in serum free light chains were seen in other patients. MV-NIS is capable of replicating before being cleared by the immune system. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated myeloma.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dispenzieri A, Tong C, LaPlant B, et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia. 2017. PMID: 28439108. doi:10.1038/leu.2017.120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。